• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康儿童与新诊断克罗恩病患者肠道微生物组的差异。

Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn's disease.

机构信息

Department of Pediatrics, Gastroenterology and Nutrition, Faculty of Medicine, Jagiellonian University Medical College, Wielicka 265, Kraków, 30-663, Poland.

Division of Molecular Medical Microbiology, Department of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Czysta 18, Kraków, 31-121, Poland.

出版信息

Sci Rep. 2019 Dec 11;9(1):18880. doi: 10.1038/s41598-019-55290-9.

DOI:10.1038/s41598-019-55290-9
PMID:31827191
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6906406/
Abstract

The aetiology of inflammatory bowel diseases (IBD) seems to be strongly connected to changes in the enteral microbiome. The dysbiosis pattern seen in Crohn's disease (CD) differs among published studies depending on patients' age, disease phenotype and microbiome research methods. The aims was to investigate microbiome in treatment-naive paediatric patients to get an insight into its structure at the early stage of the disease in comparison to healthy. Stool samples were obtained from controls and newly diagnosed patients prior to any intervention. Microbiota was analysed by 16SrRNAnext-generation-sequencing (NGS). Differences in the within-sample phylotype richness and evenness (alpha diversity) were detected between controls and patients. Statistically significant dissimilarities between samples were present for all used metrics. We also found a significant increase in the abundance of OTUs of the Enterococcus genus and reduction in, among others, Bifidobacterium (B. adolescentis), Roseburia (R.faecis), Faecalibacterium (F. prausnitzii), Gemmiger (G. formicilis), Ruminococcus (R. bromii) and Veillonellaceae (Dialister). Moreover, differences in alpha and beta diversities in respect to calprotectin and PCDAI were observed: patients with calprotectin <100 µg/g and with PCDAI below 10 points vs those with calprotectin >100 µg/g and mild (10-27.7 points), moderate (27.5-40 points) or severe (>40 points) CD disease activity had higher richness and diversity of gut microbiota. The results of our study highlight reduced diversity and dysbiosis at the earliest stage of the disease. Microbial imbalance and low abundance of butyrate-producing bacteria, including Bifidobacterium adolescentis, may suggest benefits of microbial modification therapy.

摘要

炎症性肠病(IBD)的病因似乎与肠内微生物组的变化密切相关。在克罗恩病(CD)中观察到的失调模式因发表研究的患者年龄、疾病表型和微生物组研究方法而异。本研究旨在调查未经治疗的儿科患者的微生物组,以深入了解其在疾病早期的结构,并与健康者进行比较。在进行任何干预之前,从对照组和新诊断的患者中获取粪便样本。通过 16SrRNA 下一代测序(NGS)分析微生物群。在对照组和患者之间检测到样本内分类丰富度和均匀度(alpha 多样性)的差异。所有使用的指标都存在样本之间的统计学显著差异。我们还发现肠球菌属 OTUs 的丰度显著增加,双歧杆菌(B. adolescentis)、罗氏菌(R. faecis)、粪杆菌(F. prausnitzii)、Gemmingger 菌(G. formicilis)、瘤胃球菌(R. bromii)和韦荣氏菌科(Dialister)等减少。此外,在 alpha 和 beta 多样性方面观察到与钙卫蛋白和 PCDAI 的差异:钙卫蛋白<100μg/g 且 PCDAI 低于 10 分的患者与钙卫蛋白>100μg/g 且轻度(10-27.7 分)、中度(27.5-40 分)或重度(>40 分)CD 疾病活动的患者相比,肠道微生物群的丰富度和多样性更高。我们的研究结果强调了疾病最早阶段的多样性降低和失调。微生物失衡和丁酸产生菌(包括双歧杆菌)丰度降低,可能提示微生物修饰治疗有益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbc/6906406/1611b2f08a47/41598_2019_55290_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbc/6906406/0a8b8a9ef38a/41598_2019_55290_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbc/6906406/1c67f981ad03/41598_2019_55290_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbc/6906406/78f0b4a12046/41598_2019_55290_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbc/6906406/2d3b5e9fa083/41598_2019_55290_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbc/6906406/b5301d6b6b84/41598_2019_55290_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbc/6906406/1611b2f08a47/41598_2019_55290_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbc/6906406/0a8b8a9ef38a/41598_2019_55290_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbc/6906406/1c67f981ad03/41598_2019_55290_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbc/6906406/78f0b4a12046/41598_2019_55290_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbc/6906406/2d3b5e9fa083/41598_2019_55290_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbc/6906406/b5301d6b6b84/41598_2019_55290_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbc/6906406/1611b2f08a47/41598_2019_55290_Fig6_HTML.jpg

相似文献

1
Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn's disease.健康儿童与新诊断克罗恩病患者肠道微生物组的差异。
Sci Rep. 2019 Dec 11;9(1):18880. doi: 10.1038/s41598-019-55290-9.
2
Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease.克罗恩病患者粪便微生物群落中产生丁酸盐的细菌种类丰度降低
Digestion. 2016;93(1):59-65. doi: 10.1159/000441768. Epub 2016 Jan 14.
3
Profiles and interactions of gut microbiome and intestinal microRNAs in pediatric Crohn's disease.儿科克罗恩病中肠道微生物组和肠道 microRNAs 的特征及相互作用。
mSystems. 2024 Sep 17;9(9):e0078324. doi: 10.1128/msystems.00783-24. Epub 2024 Aug 16.
4
IL23R-Protective Coding Variant Promotes Beneficial Bacteria and Diversity in the Ileal Microbiome in Healthy Individuals Without Inflammatory Bowel Disease.IL23R 保护性编码变异促进健康个体回肠微生物组中有益细菌和多样性,而不会引起炎症性肠病。
J Crohns Colitis. 2019 Mar 30;13(4):451-461. doi: 10.1093/ecco-jcc/jjy188.
5
Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease.中国炎症性肠病患者的粪便微生物失调。
World J Gastroenterol. 2018 Apr 7;24(13):1464-1477. doi: 10.3748/wjg.v24.i13.1464.
6
Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease.分析内镜刷取样本发现炎症性肠病存在黏膜相关的菌群失调。
J Gastroenterol. 2018 Jan;53(1):95-106. doi: 10.1007/s00535-017-1384-4. Epub 2017 Aug 29.
7
Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease.肠道菌群失调、炎症与治疗反应:一项针对新诊断的炎症性肠病儿科患者的纵向研究。
Genome Med. 2016 Jul 13;8(1):75. doi: 10.1186/s13073-016-0331-y.
8
Characteristics of Faecal Microbiota in Paediatric Crohn's Disease and Their Dynamic Changes During Infliximab Therapy.儿童克罗恩病粪便微生物群特征及其在英夫利昔单抗治疗中的动态变化。
J Crohns Colitis. 2018 Feb 28;12(3):337-346. doi: 10.1093/ecco-jcc/jjx153.
9
Siblings of patients with Crohn's disease exhibit a biologically relevant dysbiosis in mucosal microbial metacommunities.克罗恩病患者的兄弟姐妹表现出黏膜微生物元群落中具有生物学相关性的失调。
Gut. 2016 Jun;65(6):944-53. doi: 10.1136/gutjnl-2014-308896. Epub 2015 Apr 8.
10
Alterations in the relative abundance of correlate with changes in fecal calprotectin in patients with ileal Crohn's disease: a longitudinal study.回肠克罗恩病患者中,[具体内容]相对丰度的改变与粪便钙卫蛋白的变化相关:一项纵向研究。 (你提供的原文中“Alterations in the relative abundance of ”后面缺少具体内容)
Scand J Gastroenterol. 2019 May;54(5):577-585. doi: 10.1080/00365521.2019.1599417. Epub 2019 May 19.

引用本文的文献

1
Combining site-specific gut microbiome and mycobiome profiling with clinical indicators for effective management of pediatric Crohn's disease.将特定部位的肠道微生物组和真菌微生物组分析与临床指标相结合,以有效管理儿童克罗恩病。
iScience. 2025 Jul 18;28(8):113160. doi: 10.1016/j.isci.2025.113160. eCollection 2025 Aug 15.
2
A glycan atlas of the mammalian intestine through ontogeny and inflammation.通过个体发育和炎症构建的哺乳动物肠道聚糖图谱。
bioRxiv. 2025 May 28:2025.03.06.641959. doi: 10.1101/2025.03.06.641959.
3
Markers of bacterial translocation as a possible indicator of subclinical inflammation in pediatric inflammatory bowel diseases patients.

本文引用的文献

1
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2.使用QIIME 2进行可重复、交互式、可扩展和可延伸的微生物组数据科学研究。
Nat Biotechnol. 2019 Aug;37(8):852-857. doi: 10.1038/s41587-019-0209-9.
2
Dependence of Colonization of the Large Intestine by on the Treatment of Crohn's Disease.[具体物质名称缺失]对大肠的定植情况与克罗恩病治疗的相关性。
Pol J Microbiol. 2019;68(1):121-126. doi: 10.21307/pjm-2019-014.
3
The microbiome of Crohn's disease aphthous ulcers.克罗恩病阿弗他溃疡的微生物群
细菌易位标志物作为小儿炎症性肠病患者亚临床炎症的可能指标。
Prz Gastroenterol. 2025;20(2):185-191. doi: 10.5114/pg.2025.151888. Epub 2025 Jun 6.
4
Dietary patterns influencing the human colonic microbiota from infancy to centenarian age: a narrative review.从婴儿期到百岁老人期影响人类结肠微生物群的饮食模式:一项叙述性综述
Front Nutr. 2025 Jun 4;12:1591341. doi: 10.3389/fnut.2025.1591341. eCollection 2025.
5
Role and mechanism of gut microbiota-host interactions in the pathogenesis of Crohn's disease.肠道微生物群与宿主相互作用在克罗恩病发病机制中的作用及机制
Int J Colorectal Dis. 2025 May 28;40(1):130. doi: 10.1007/s00384-025-04917-7.
6
Irritable Bowel Syndrome with Diarrhea (IBS-D): Effects of CBM588 Probiotic on Gastrointestinal Symptoms, Quality of Life, and Gut Microbiota in a Prospective Real-Life Interventional Study.腹泻型肠易激综合征(IBS-D):一项前瞻性真实生活干预研究中CBM588益生菌对胃肠道症状、生活质量和肠道微生物群的影响
Microorganisms. 2025 May 15;13(5):1139. doi: 10.3390/microorganisms13051139.
7
Evaluation of microbiome composition combined with serum untargeted metabolomic profiling in newly diagnosed children with inflammatory bowel disease.新诊断的炎症性肠病患儿微生物组组成与血清非靶向代谢组学分析相结合的评估
Arch Med Sci. 2024 Jul 25;21(2):416-424. doi: 10.5114/aoms/190623. eCollection 2025.
8
Gut microbiota-derived short-chain fatty acids and their role in human health and disease.肠道微生物群衍生的短链脂肪酸及其在人类健康与疾病中的作用。
Nat Rev Microbiol. 2025 May 13. doi: 10.1038/s41579-025-01183-w.
9
Gut Microbiota in Different Treatment Response Types of Crohn's Disease Patients Treated with Biologics over a Long Disease Course.长期病程中接受生物制剂治疗的不同治疗反应类型克罗恩病患者的肠道微生物群
Biomedicines. 2025 Mar 13;13(3):708. doi: 10.3390/biomedicines13030708.
10
Gut Microbiota Serves as a Crucial Independent Biomarker in Inflammatory Bowel Disease (IBD).肠道微生物群是炎症性肠病(IBD)中一个关键的独立生物标志物。
Int J Mol Sci. 2025 Mar 11;26(6):2503. doi: 10.3390/ijms26062503.
Gut Pathog. 2018 Oct 10;10:44. doi: 10.1186/s13099-018-0265-6. eCollection 2018.
4
Variability of core microbiota in newly diagnosed treatment-naïve paediatric inflammatory bowel disease patients.新诊断未经治疗的小儿炎症性肠病患者核心微生物群的变异性。
PLoS One. 2018 Aug 13;13(8):e0197649. doi: 10.1371/journal.pone.0197649. eCollection 2018.
5
Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2's q2-feature-classifier plugin.利用 QIIME 2 的 q2-feature-classifier 插件优化标记基因扩增子序列的分类学分类。
Microbiome. 2018 May 17;6(1):90. doi: 10.1186/s40168-018-0470-z.
6
Multi-omics differentially classify disease state and treatment outcome in pediatric Crohn's disease.多组学差异分析可区分小儿克罗恩病的疾病状态和治疗结果。
Microbiome. 2018 Jan 15;6(1):13. doi: 10.1186/s40168-018-0398-3.
7
Meta-analysis of gut microbiome studies identifies disease-specific and shared responses.基于宏基因组关联研究的肠道微生物组分析鉴定出疾病特异性和共享反应。
Nat Commun. 2017 Dec 5;8(1):1784. doi: 10.1038/s41467-017-01973-8.
8
Characteristics of Faecal Microbiota in Paediatric Crohn's Disease and Their Dynamic Changes During Infliximab Therapy.儿童克罗恩病粪便微生物群特征及其在英夫利昔单抗治疗中的动态变化。
J Crohns Colitis. 2018 Feb 28;12(3):337-346. doi: 10.1093/ecco-jcc/jjx153.
9
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.21 世纪全球炎症性肠病的发病率和流行率:基于人群的系统综述研究。
Lancet. 2017 Dec 23;390(10114):2769-2778. doi: 10.1016/S0140-6736(17)32448-0. Epub 2017 Oct 16.
10
Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management.综述文章:炎症性肠病中的肠道微生物组——微生物管理途径。
Aliment Pharmacol Ther. 2018 Jan;47(1):26-42. doi: 10.1111/apt.14384. Epub 2017 Oct 16.